What Should You know About Biogen (BIIB) Before Investing?

After moving 1.2% during today's afternoon session, Biogen is now trading at a price of $240.31 per share. On average, analysts give it a target price of $330.76.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

Potential Biogen Investors Should Analyze the Following:

  • Biogen has moved -14.0% over the last year.

  • The company has a price to earnings growth (PEG) ratio of 33.68. A number between 0 and 1 could mean that the market is undervaluing Biogen's estimated growth potential

  • Its Price to Book (P/B) ratio is 2.41

Understanding Biogen's Operating Margins

Date Reported Total Revenue ($ k) Operating Expenses ($ k) Operating Margins (%) YoY Growth (%)
2023 9,971,500 6,850,200 31 -11.43
2022 10,173,400 6,581,600 35 34.62
2021 10,981,700 9,236,500 26 -31.58
2020 13,444,600 8,397,100 38 -24.0
2019 14,377,900 7,335,300 50 13.64
2018 13,452,900 7,564,300 44

Over the last 6 years, Biogen's operating margins have averaged 37.3%, which is better than the 15.02% Biotechnology industry average. We also note that the company's operating margins have a high coefficient of variability at 73.6%. However the firm's margins are declining at a compounded yearly rate of -5.5%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

ON FOCUS